About Immuron

Immuron Ltd is a publicly listed Australian biopharmaceutical company (ASX: IMC) focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans.

Immuron is a uniquely positioned biotechnology company in view of its versatile technology platform, comprising dairy derived polyclonal antibodies, capable of generating a wide range of products with a high safety profile.  This high safety profile makes it possible to complete pre-clinical studies relatively quickly and raises the prospect that the clinical development of Immuron’s products will be expedited.

The Company already has one product the market. It also has several clinical phase products as well as several products in research and preclinical stages. Immuron’s products and product candidates address a range of gastrointestinal, infectious and immune-mediated diseases such as Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), influenza and HIV.

Both clinical and preclinical studies to date have demonstrated efficacy and safety for a number of our products and product candidates. For example, Travelan™ is effective in preventing Travellers’ Diarrhoea, IMM124-E has demonstrated efficacy against non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes (T2D) and IMM 272 is effective in preventing rotavirus infection.